Cases
Representative Matters: Represented Framerate, Inc., one of the largest
fastest growing independent social video networks in esports
online gaming which generates millions of views per month across Instagram
Facebook, in its sale to Super League Gaming, Inc., which provides a platform for competitive
social gameplay experiences
is exp
ing its business of running esports events.
Represented 1CellBiO on a research collaboration with UCB to validate
deploy the inDrop high throughput single cell RNA sequencing platform.
Represented Ology Bioservices Inc. on an exclusive license to Trethera Corporation for the global development, manufacturing
marketing of Triapine (3-AP)
all formulations, for the treatment of hematological malignancies.
Represented Lin BioScience on a worldwide exclusive licensing agreement with Columbia University
Memorial Sloan Kettering Cancer Center for portfolio for a novel inhibitor of CDC7 kinase.
Represented Lin Bioscience on an exclusive licensing agreement with the University of Sydney for a microtubule-targeting agent to treat brain cancer.
Represented Ology Bioservices Inc. in the closing of a sale-leaseback transaction with Senior Housing Properties Trust (SHP), whereby Ology Bioservices sold its newly constructed Advanced Development
Manufacturing Biosafety Level-3 capable Facility in Alachua, Florida to SHP for $45 million
entered into a 15-year lease of such facility.
Represented Enumeral Biomedical Holdings, Inc. (ENUM) in connection with its License
Transfer Agreement with Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals GmbH whereby Pieris is licensing from Enumeral specified intellectual property related to Enumeral's anti-PD-1 antibody program ENUM 388D4 for the potential development
commercialization by Pieris of novel multispecific therapeutic proteins comprising fusion proteins based on Pieris' Anticalins class of therapeutic proteins
Enumeral antibodies in the field of oncology.
Represented Ology Bioservices Inc., in a license amendment with Takeda, which exp
ed Takeda's commercialization
technology access rights related to Ology's Vero cell technology platform - a cell culture-based platform for vaccine production which Ology acquired from Baxalta, formerly Baxter International's BioScience division.
Represented Ology Bioservices Inc. in the purchase from Baxter International Inc. (BAX) of its proprietary Vero cell technology
related assets, including its production facility in Bohumil, Czech Republic.
Represented EnEvolv, a genome engineering company in a Series A Financing with Cultivian S
box Venture Partners.
Represented Squad in the sale of Kerbal Space Program to Take Two Interactive.
Represented the video game company Trendy Entertainment, the developer of Dungeon Defenders, in connection with an investment from Insight Ventures.
Represented Anellotech, Inc. in negotiations with Johnson Matthey Process Technologies on an alliance to co-develop advanced catalyst systems for Anellotech's Catalytic Fast Pyrolysis (CFP) Process for production of bio-based benzene, toluene
paraxylene for the chemical industry.
Represented a large online MMO RTS video game on several DMCA matters.
Represented Mad Doc Software on the development of videogames such as Empire Earth II, Star Trek Armada, Empire Earth III
other titles.
Represented Roostr, an open marketplace for mobile games, in their acquisition by Chartboost, Inc.
Represented Anellotech Inc. in negotiations with IFP Energies nouvelles (IFPEN)
its subsidiary Axens on a strategic alliance to develop
commercialize a new technology for the low cost production of bio-based benzene, toluene
paraxylene using Anellotech's process of Catalytic Fast Pyrolysis (CFP) of non-food biomass.
Represented Enumeral Biomedical Corp. in closing an alternative public offering, allowing the company to raise $21.5 million in a private placement financing in connection with a reverse merger into a publicly held company.
Represented Ology Bioservices Inc. in negotiating $30 million loan facility from Hercules Technology Growth Capital.
Represented a biotechnology company with platform technology in antibodies in negotiation of four key university licenses
a collaboration with a major pharmaceutical.
Represented a life sciences company in the acquisition of Phase II
Phase III drugs out of Chapter 7
Chapter 11 proceedings through Section 363 acquisitions.
Negotiated sale of BioTrove to Life Technologies (listed as one of the top 10 in vitro diagnostic deals in 2009 by Price Waterhouse Coopers in their publication Diagnostics 2011 ).
Represented an early stage bio-chemical company in the negotiation of a license from University of Massachusetts for technologies for the production of petrochemicals from biomass
with respect to collaborations with major industry players
follow on collaborations.
Represented an early stage company with novel technology in the field of antibodies in successive financings.
Represented Sage Science, a life sciences company focused on sample prep for the life sciences industry, in distribution agreements
capital transactions.
Negotiated a license agreement between the University of Bergen
OvaGene Oncology to biomarker-related IP for the development of clinical laboratory tests for identifying high-risk endometrial cancer patients
predicting chemoradiation resistance in cervical cancer.
Member of deal team for Takeda's acquisition of Millennium Pharmaceuticals.
Represented Saladax in the licensing of a theranostics technology to Myriad Genetics.
Represented an early stage company located in Australia in the licensed of a novel attenuated live flu vaccine developed in Russia to a major U.S. pharmaceutical company.
Represented German biotech in collaborations on transdermal drug delivery device with several major U.S.
EU pharmaceutical companies.
Represented hotel developer in the acquisition, development
sale of luxury hotel properties in Turkey, London, Palm Beach
Boston.
